TABLE 4.
Baseline characteristics and outcomes of included patients, divided by treatment strategies
| Oncologic | First oncologic, later urologic | Combined/unknown timeline | First urologic, later oncologic | Urologic | |
|---|---|---|---|---|---|
| First author | Atas, Castagnetti (n = 3), Ergenc, Kumar (n = 2), Musa, Ocheni, Veljkovic | Becerra, Gupta, Morano | Gaye, Hazra, Huei, Misha, Purohit Syarif, Sossa Mel | Abd El Salam, Avci, Chang, Clark, Dhar, Dogra, Ervie, Farhan, Gupta and Agrawal, Jameel (n = 2), Khan, Manuel, Minckler, Narendra, Nerli, Rajabto, Patil, Ponniah, Qu, Sachdeva, Shaeer, Singh Dhanjum Swapna, Thakur, Ullah | Almeena, Ammouri, Htun, Ocheni, Sareen, Sun, Tazi |
| No. of patients studied | 10 | 3 | 7 | 26 | 7 |
| Age (years) | 18 (9.0–21.8) | 23 (12–NA) | 27 (17–46) | 20.5 (18–31) | 27 (21–36) |
| WBC count, ×109/L | 280 (192–416) | 364 (282–NA) | 354 ± 163 | 295 (215–401) | 450 (377–501) |
| Time to treatment (days) | 3.5 (1–10) | 3 (2–NA) | 2 (1–5) | 1 (0.38–4.0) | 0.92 (0.51–2.21) |
| Resolution, yes | 10 (100%) |
2 (67%) NB: 33% missing |
6 (87.5%) NB: 14% missing |
22 (84.6%) NB: 12% missing |
6 (85.7%) NB: 14% missing |
| Erectile dysfunction, yes |
3 (30%) NB: 70% missing |
0 (0%) NB: 67% missing |
2 (28.6.%) NB: 57% missing |
4 (15.4%) NB: 50% missing |
0 (14.3%) NB: 86% missing |
Note: Numbers (% of total number patients) unless otherwise specified. Missing data when >10% is mentioned. Parameters are presented as mean ± standard deviation when normally distributed, or as mean (Quartile 1–Quartile 3) when not normal distributed.
Abbreviations: NA, not applicable; WBC, white blood cells.